跳至主要内容
临床试验/JPRN-jRCT2021190021
JPRN-jRCT2021190021进行中(未招募)1 期

Phase I/IIa study of unoprostone release drug (URD) for safety and efficacy assessment on retinitis pigmentosa

Abe Toshiaki0 个研究点目标入组 3 人开始时间: 2020年2月19日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • 1) Retinitis pigmentosa patients
  • 2) Available for written informed consent
  • 3) Patients older than 20 years old
  • 4) Patients who agree to participate in this study
  • 5) Decimal visual acuities of both eyes are more than 0.1, and interocular difference in visual acuity is less than or equal to 0.21 (logMAR converted value)
  • 6) Ptients with no difficulty in evaluateing the thickness of IS/OS line in fovea by optical coherence tomography
  • 7) Patients with no Interocular difference in the condition of lens
  • 8) Visual field measured by Goldmann perimeter V-4e is more than 5 degree at the center area of vision, and interocular difference in visual field is less than 34%
  • 9) Interocular difference in the MD value measured by Humphrey perimeter (10-2 program) is less than 12 dB, and difference in the mean retinal sensitivity measured in repeating tests of visit 1 and 2 or visit 2 and 3 using Humphrey perimeter (10-2 program) is less than 3 dB, and the mean retinal sensitivity measured by Humphrey perimeter (10-2 program) is less than 30 dB (central 4 points)

排除标准

  • 1) Length of eyeball is less than 21 mm or more than 27 mm
  • 2) Difference in interocular length of eyeball is more than 2 mm
  • 3) Patients who will have ophthalmic surgery except URD implantation/removal
  • 4) Patients who had intraocular surgery within 24 weeks before URD implantation
  • 5) Patients who had enucleated eye
  • 6) Patients with galucoma and ocular hypertension
  • 7) Patients with previous history of optic nerve disease and retinal detachment
  • 8) Patients with complications of diabetic retinopathy, cone-rod dystrophy, and progressive retinal disease
  • 9) Patients with complications of macular edema, cyst, epimacular membrane, and macular traction by OCT examination
  • 10) Patients with intense choroid atrophy such as intense myopia and posterior staphyloma
  • 11) Patients with complications of extraocular inflammation, infection, and severe dry eye
  • 12) Patients with previous treatment history using isopropyl unoprostone and helenien within 12 weeks before informed consent
  • 13) Patients with calcium antagonist and vitamin A within 12 weeks before informed consent
  • 14) Patients who have drug allergies with ophthalmic anesthetic, fluorescein, and prostaglandin
  • 15) Pregnant woman, maternal, lactating woman
  • 16) Patients with complications of severe kidney disease, liver disease, cranial nerve disease, Heart disease, and malignant tumor
  • 17) Patients with complications of autoimmune disease, diabetes, mental disorders, cognitive impairment, and hay fever
  • 18) Patients who had other clinical trial and clinical research within 24 weeks before informed consent
  • 19) Patients who have been considered inappropriate as study subjects by the investigator or sub-investigator

研究者

发起方
Abe Toshiaki

相似试验